22 May 2015 | News | By BioSpectrum Bureau
Abbott partners with Japan's Sekisui
Coagulation tests measure a person's blood clotting ability, which can help doctors assess risks of excessive bleeding or developing clots
Singapore: Abbott Laboratories has inked a pact with Japan's Sekisui to offer coagulation testing solutions for laboratories worldwide. Under the deal, Abbott will be the exclusive distributor of Sekisui's new CP3000 coagulation instrument in the US, Europe and other regions that recognize CE Mark.
Coagulation tests measure a person's blood clotting ability, which can help doctors assess risks of excessive bleeding or developing clots. The test helps clinicians in diagnosis of blood-related disorders such as haemophilia and thrombosis.
"Abbott is committed to providing testing solutions that healthcare providers rely on for actionable information in diagnosing and treating various medical conditions," said, Mr Jaime Contreras, senior vice president, commercial operations, diagnostics, Abbott. "Collaborating with Sekisui broadens our offerings within hematology, providing an important component needed to improve care for people around the world."
Sales of CP3000 are expected to begin later this year in Europe, countries that recognize CE Mark and non-regulated countries, and in the US in 2016. Abbott will have non-exclusive distribution rights with Sekisui in China, Hong Kong, Japan and Macau.